Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
This project shall be implemented through incorporation of a new joint venture company in Zambia
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
Subscribe To Our Newsletter & Stay Updated